Evidence map›Paper›PMID 34938422›Full record

ArticleJournal of healthcare engineering2021

Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.

Shan Liu, Xiaocheng Huang, Jin Wen, Fangfang Fu, Huifen Wang

Open access · hybridAbstract read
In one paragraph

Article in Journal of healthcare engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Application Value of Evidence-Based Care in Patients with Lung Cancer Chemotherapy.Computational and mathematical methods in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shan LiuDepartment of Nursing, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
Xiaocheng HuangDepartment of Nursing, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
Jin WenDepartment of Chest Oncology, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
Fangfang FuDepartment of Chest Oncology, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
Huifen WangDepartment of Nursing, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.ORCID 0000-0001-9699-342X
Hubei Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with tegafur, gimeracil, and oteracil potassium (TS-1) and its influence on quality of life (QOL). Methods: Clinical data of 92 patients with advanced squamous cell carcinoma of the lung treated with erlotinib and TS-1 in our hospital (January 2017-January 2021) were retrospectively analyzed. Forty-six patients receiving conventional nursing were set as the control group (CG), and other 46 patients receiving evidence-based nursing intervention additionally were set as the study group (SG). The clinical observation indexes of the two groups were compared and analyzed. Results: No obvious difference in general data between both groups ( Conclusion: Application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with TS-1 can help patients to relieve pain, improve their psychological state, reduce the incidence of adverse reactions, significantly improve the QOL, and also enhance the satisfaction of clinical nursing.

Indexed as

Carcinoma, Squamous CellQuality of LifeErlotinib HydrochlorideEvidence-Based NursingHumansLungOxonic AcidPotassiumPyridinesRetrospective StudiesTegafurErlotinib HydrochloridegimeracilOxonic AcidPotassiumPyridinesTegafur

Identifiers

PMID34938422
PMCPMC8687769
OpenAlexW4200542589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.